Anabolic–androgenic steroid abuse: psychiatric manifestations and treatment

Introduction Anabolic-androgenic steroids (AAS) are synthetic derivatives of which frequently utilized in order to increase muscle mass and strength. Estimates AAS abuse vary according different studies. However, a global lifetime prevalence 3.3% has been reported. The increasing illicit use over the years raised serious public health concerns. Objectives To report clinical case review psychopathology associated with its treatment. Methods authors conducted non-systematic on Pubmed database terms “anabolic-androgenic steroids”, “abuse” “psychiatric manifestations”. Results A 25-year-old male patient history body dysmorphic disorder was admitted emergency services following severe psychomotor agitation verbal physical aggression towards his family members. He explained he had begun using prior improve appearance. Recently administering injections more regular basis restricting food water intake. His sleep-wake cycle disrupted began experiencing anxiety persecutory ideation. Additionally, increased reported numerous conflicts members took place weeks previous psychiatric observation. symptoms such as violence, mania less commonly psychosis suicidal Moreover, prolonged can lead dependence withdrawal suspension. biphasic model steroid described. First there is brief hyperadrenergic state opoid-like then followed by period depression craving. During this phase fatigue, joint pain, insomnia, may occur. There no established guidelines for Acute care should follow similar course one other forms substance induced-agitation: firstly, least invasive interventions be implemented. If medication required, haloperidol effective, although evidence scarce. Benzodiazepines considered, not In regards long term care, discontinuation vital conjunction proper management symptoms. presents opioid-like withdrawal, treatment clonidine initiated. medically prescribed suggested alleviate Other options human chorionic gonadotrophin clomiphene have also proposed. Conclusions concern. Clinicians aware effects possible courses. Disclosure Interest None Declared